- Home
- QNC vs LRMR Comparison
QNC vs LRMR Comparison
Compare QNC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QNC | LRMR |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Canada | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.7M | 455.8M |
| IPO Year | 2026 | 2014 |
Fundamental Metrics
Financial Performance| Metric | QNC | LRMR |
|---|---|---|
| Price | $2.64 | $4.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 524.5K | ★ 1.7M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $1.73 |
| 52 Week High | $3.41 | $6.42 |
Technical Indicators
Market Signals| Indicator | QNC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 50.94 |
| Support Level | $2.03 | $3.14 |
| Resistance Level | N/A | $5.36 |
| Average True Range (ATR) | 0.24 | 0.29 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 72.38 | 49.56 |
Price Performance
Historical ComparisonAbout QNC Quantum eMotion Corp. Common Shares
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.